AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 78, Issue 11 1479-1481, Copyright © 1988 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemminki, E
Right arrow Articles by McKinlay, S M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemminki, E
Right arrow Articles by McKinlay, S M
Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86.

E Hemminki, D L Kennedy, C Baum and S M McKinlay

Department of Public Health, University of Helsinki, Finland.

This paper describes changes in the prescribing of noncontraceptive estrogens and progestins, using data from pharmaceutical marketing surveys. The number of estrogen prescriptions decreased from 1975 to 1980, and then increased through 1986. Progestin use has increased since 1982; concomitant use of estrogens and progestins increased over time and was common in 1986. The trends suggest that the use of estrogens, particularly the combined use of estrogens and progestins, will continue to increase.




This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
M. S. Linet
Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond
Am. J. Epidemiol., June 15, 2008; 167(12): 1416 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
C. M. Greiser, E. M. Greiser, and M. Doren
Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis
Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
B. L. Strom, R. Schinnar, A. L. Weber, G. Bunin, J. A. Berlin, M. Baumgarten, A. DeMichele, S. C. Rubin, M. Berlin, A. B. Troxel, et al.
Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer
Am. J. Epidemiol., October 15, 2006; 164(8): 775 - 786.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al.
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
C. M. Greiser, E. M. Greiser, and M. Doren
Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Hum. Reprod. Update, November 1, 2005; 11(6): 561 - 573.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. I. Li, B. O. Anderson, J. R. Daling, and R. E. Moe
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
JAMA, March 19, 2003; 289(11): 1421 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. A. Newcomb, L. Titus-Ernstoff, K. M. Egan, A. Trentham-Dietz, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer
Postmenopausal Estrogen and Progestin Use in Relation to Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 593 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T. E. C. Workshop Group
Continuation rates for oral contraceptives and hormone replacement therapy
Hum. Reprod., August 1, 2000; 15(8): 1865 - 1871.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
J Natl Cancer Inst, February 16, 2000; 92(4): 328 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. M. Gapstur, M. Morrow, and T. A. Sellers
Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology: Results of the Iowa Women's Health Study
JAMA, June 9, 1999; 281(22): 2091 - 2097.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
N. L. Keating, P. D. Cleary, A. S. Rossi, A. M. Zaslavsky, and J. Z. Ayanian
Use of Hormone Replacement Therapy by Postmenopausal Women in the United States
Ann Intern Med, April 6, 1999; 130(7): 545 - 553.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Prior
Perimenopause: The Complex Endocrinology of the Menopausal Transition
Endocr. Rev., August 1, 1998; 19(4): 397 - 428.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Public Health Association